Modafinil therapy and mental status following aneurysmal subarachnoid hemorrhage: comprehensive stroke-center analysis
Stefan W. Koester,Kavelin Rumalla,Joshua S. Catapano,Samuel R. Sorkhi,Varun Mahadevan,Gregory P. Devine,Anant Naik,Ethan A. Winkler,Robert F. Rudy,Jacob F. Baranoski,Tyler S. Cole,Christopher S. Graffeo,Visish M. Srinivasan,Ruchira M. Jha,Ashutosh P. Jadhav,Andrew F. Ducruet,Felipe C. Albuquerque,Michael T. Lawton
DOI: https://doi.org/10.1016/j.wneu.2024.02.056
IF: 2.21
2024-02-17
World Neurosurgery
Abstract:Background Disorders of consciousness impair early recovery after aneurysmal subarachnoid hemorrhage (aSAH). Modafinil, a wakefulness-promoting agent, is efficacious for treating fatigue in stroke survivors, but data in the acute setting is scarce. This study sought to assess the effects of modafinil use on mental status after aSAH. Methods Modafinil timing and dosage, neurological examination, intubation status, and physical/occupational therapy (PT/OT) participation were documented. Repeated-measures paired tests were used for a before-after analysis of modafinil recipients. Propensity score matching (1:1 nearest neighbor) for modafinil and no-modafinil cohorts was used to compare outcomes. Results Modafinil (100–200 mg/day) was administered to 21% (88/422) of aSAH patients for a median (IQR) duration of 10.5 (4–16) days and initiated 14 (7–17) days after aSAH. Improvement in mentation (alertness, orientation, or Glasgow Coma Scale [GCS] score) was documented in 87.5% (n=77) of modafinil recipients within 72 hours and 86.4% (n=76) at discharge. Of 37 intubated patients, 10 (27%) were extubated within 72 hours after modafinil initiation. PT/OT noted increased alertness/participation in 47 of 56 modafinil patients (83.9%). After propensity score matching for baseline covariates, the modafinil cohort had a greater mean (SD) change in GCS score than the no-modafinil cohort at discharge (2.2 [4.0] vs. -0.2 [6.32], P=0.003). Conclusions A temporal relationship with improvement in mental status was noted for most patients administered modafinil after aSAH. These findings, a favorable adverse-effect profile, and implications for goals-of-care decisions favor a low threshold for modafinil initiation in aSAH patients in the acute-care setting.
surgery,clinical neurology